Community Pharmacy-focused Clinical Assessment Platform (Ph-CAP)
Lead Participant:
DEM DX LIMITED
Abstract
DemDX will deliver an urgently needed community pharmacy-focused clinical assessment platform (Ph-CAP).
The need is driven by the introduction of the Community Pharmacist Consultation Services (CPCS) to integrate community pharmacy into the urgent care and primary care systems by enabling pharmacists to take referrals from NHS 111 and general practice for minor illness symptoms (e.g., lower back pain, nausea, diarrhoea, cough, headache and migraine, sleeping problems, skins infections, sore throat, etc). The CPCS is one of the biggest workforce shake-ups in the NHS in decades, and brings two significant challenges:
* Clinical pharmacists require expanded generalist knowledge across hundreds of conditions, signs, symptoms and "red flags," recognition of patient-specific comorbidities, and awareness of frequently updated gold standard protocols. Clinical pharmacists are urgently calling for tools to support them in their expanded roles.
* GP surgeries lack confidence in CPCS. Only 13% of GP surgeries use the scheme -- minimising impact on reducing GP workloads and waiting lists (currently a record 6.84m) and improving patient pathways.
Ph-CAP builds upon DemDX's sector-leading clinical reasoning intelligent support platform (CRISP), co-developed via InnovateUK and NIHR-funded engagement in six NHS Trusts. It is a gold standard in support tools for allied health professionals.
Ph-CAP will be a revolutionary cloud-based clinical assessment tool, using AI and data to support community pharmacists in better, safer, quicker clinical assessment and treatment or referral decisions. Innovations include:
* AI allowing dynamic consideration of complex patterns and associations across 10,000s of symptoms, differentials and "red flags" in validated NICE data.
* A data-driven structure enabling community pharmacists to make sense of complex data associations to make safe, consistent decisions, with patient-centric data weighting enabling prioritisation of most probable conditions, driving accuracy of recommendations.
* Powered by an 8m-patient Oxford-Royal College of GPs dataset.
* Linking to local pathways and protocols to inform best referral options.
* Outputs are tailored to community pharmacist competencies, focusing on common minor illnesses, e.g., lower back problems.
* Ph-CAP is fully interoperable and can be seamlessly integrated into CPCS pathways.
The need is driven by the introduction of the Community Pharmacist Consultation Services (CPCS) to integrate community pharmacy into the urgent care and primary care systems by enabling pharmacists to take referrals from NHS 111 and general practice for minor illness symptoms (e.g., lower back pain, nausea, diarrhoea, cough, headache and migraine, sleeping problems, skins infections, sore throat, etc). The CPCS is one of the biggest workforce shake-ups in the NHS in decades, and brings two significant challenges:
* Clinical pharmacists require expanded generalist knowledge across hundreds of conditions, signs, symptoms and "red flags," recognition of patient-specific comorbidities, and awareness of frequently updated gold standard protocols. Clinical pharmacists are urgently calling for tools to support them in their expanded roles.
* GP surgeries lack confidence in CPCS. Only 13% of GP surgeries use the scheme -- minimising impact on reducing GP workloads and waiting lists (currently a record 6.84m) and improving patient pathways.
Ph-CAP builds upon DemDX's sector-leading clinical reasoning intelligent support platform (CRISP), co-developed via InnovateUK and NIHR-funded engagement in six NHS Trusts. It is a gold standard in support tools for allied health professionals.
Ph-CAP will be a revolutionary cloud-based clinical assessment tool, using AI and data to support community pharmacists in better, safer, quicker clinical assessment and treatment or referral decisions. Innovations include:
* AI allowing dynamic consideration of complex patterns and associations across 10,000s of symptoms, differentials and "red flags" in validated NICE data.
* A data-driven structure enabling community pharmacists to make sense of complex data associations to make safe, consistent decisions, with patient-centric data weighting enabling prioritisation of most probable conditions, driving accuracy of recommendations.
* Powered by an 8m-patient Oxford-Royal College of GPs dataset.
* Linking to local pathways and protocols to inform best referral options.
* Outputs are tailored to community pharmacist competencies, focusing on common minor illnesses, e.g., lower back problems.
* Ph-CAP is fully interoperable and can be seamlessly integrated into CPCS pathways.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| DEM DX LIMITED | £470,876 | £ 329,613 |
Participant |
||
| INNOVATE UK |
People |
ORCID iD |
| Lorin Gresser (Project Manager) |